Invokana (canagliflozin) / J&J, Daiichi Sankyo, Tanabe Pharma, Mundipharma - LARVOL DELTA

SGLT1 and SGLT2 Modulation in Antidiabetic Therapy-Comparative Insights into Gliflozins and Natural Compounds Resveratrol and Viniferin. (PubMed, Pharmaceuticals (Basel)) - "Synthetic agents like sotagliflozin or canagliflozin have been discovered recently and are currently used as antidiabetic therapy, providing great efficacy in modulation of glucose transport. In regard to stilbenoids, they offer promising in vitro results, though in vivo studies and clinical trials are scarce. Understanding resveratrol and viniferin pharmacokinetics, target interactions, and limitations is vital for their development as potential complementary or even alternative antidiabetic therapies."

Journal • Review • Diabetes • Metabolic Disorders

Safety Profile of SGLT-2 Inhibitors in Older Adults: A Systematic Review and Network Meta-Analysis. (PubMed, Med Sci (Basel)) - "In older adults, SGLT2i maintain a favorable benefit-risk profile, with significant reductions in mortality and SAEs, though risks of genital infections and volume depletion require vigilance. The risk of genital infections exhibits a strong dose-response relationship and increases markedly in the oldest adults, while the mortality benefit appears to be most pronounced in those aged 75 years and older. This study provides actionable insights for personalized therapy in geriatric care."

Clinical • Journal • Retrospective data • Review • Acute Kidney Injury • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease

THE MORE SEVERE INITIAL EGFR DIP AFTER ADMINISTRATION OF SGLT2I, THE BETTER RENOPROTECTIVE EFFECT (ISN-WCN 2026) - "In this follow-up survey, we evaluated if severity of initial GFR dip might associate tubulointerstitial biomarker and also one year-eGFR slope.Methods The FAGOTTO trial was the open-labeled randomized (1:1) study treated with Canagliflozin (Group CA) or control groups (Group CO) in DKD pts with 30 ≤ estimated GFR (eGFR) ≤ 60 mL/min/1.73 m2...When analyzed using multiple regression adjusting for age, albuminuria, mean blood pressure, treatment group and baseline eGFRcr, a positive correlation was observed between depth of initial eGFRcr dip and total eGFRcr slope (estimated value 0.25, P = 0.0386) as well as chronic eGFRcr slope (0.79, P < 0.001), that means the more severe dip produced the milder eGFRcr slope.Download: Download high-res image (121KB)Download: Download full-size imageConclusion In this analysis, the severity of initial dip was no association with induction tubulointerstitial disorder and rather suggested a good prognostic marker. Although further..."

Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Nephrology • Renal Disease • Type 2 Diabetes Mellitus • B2M • CCL2 • EGFR • FABP1

IMPACT OF POLYPHARMACY ON THE EFFICACY AND SAFETY OF SGLT2 INHIBITORS IN PATIENTS WITH CHRONIC KIDNEY DISEASE: INSIGHTS FROM THE CREDENCE TRIAL (ISN-WCN 2026) - "We assessed whether the efficacy and safety of canagliflozin is modified by polypharmacy status in patients with type 2 diabetes and CKD.Methods We conducted a post-hoc analysis of the CREDENCE trial, which evaluated the effects of canagliflozin on clinical outcomes in participants with type 2 diabetes and albuminuric CKD...Larger absolute reductions in all-cause hospitalization were observed in those experiencing polypharmacy or hyperpolypharmacy. Polypharmacy should not dissuade clinicians from using an SGLT2 inhibitor in patients with CKD for whom treatment is indicated."

Clinical • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

EFFECTS OF CANAGLIFLOZIN ON BETA-CELL FUNCTION AND INSULIN RESISTANCE IN TYPE 2 DIABETES MELLITUS: DATA FROM THE CANVAS TRIAL (ISN-WCN 2026) - "Relative effect of canagliflozin versus placebo on clinical outcomes by PIC tertileDownload: Download high-res image (93KB)Download: Download full-size imageFigure 2b. Relative effect of canagliflozin versus placebo on clinical outcomes by HOMA-IR tertileComposite renal outcome: Sustained 40% decline in eGFR, end stage renal failure, death due to renal cause"

Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Diabetic Nephropathy • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Effects of Intensification of Canagliflozin from 100 mg to 300 mg Daily on Insulin Initiation in the INTENSIFY Study (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Metabolic Disorders

SIP-AKiD: Safety and Efficacy of Canagliflozin in Advanced CKD (clinicaltrials.gov) - P4 | N=35 | Active, not recruiting | Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre | Recruiting ➔ Active, not recruiting | Trial primary completion date: Dec 2025 ➔ Mar 2026

Enrollment closed • Trial primary completion date • Chronic Kidney Disease • Renal Disease

CAN-PD: Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2028 ➔ Dec 2028 | Initiation date: Sep 2025 ➔ Feb 2026 | Trial primary completion date: Sep 2027 ➔ Feb 2028

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Chronic Kidney Disease • Fibrosis • Immunology • Nephrology • Renal Disease

SGLT2 inhibitors and AMPK crosstalk in diabetes mellitus: mechanistic insights and therapeutic applications. (PubMed, J Diabetes Metab Disord) - "Empagliflozin induces on-target energetic stress, dapagliflozin activates the FGFR1-LKB1 axis, and canagliflozin inhibits mitochondrial complex I off-target. Furthermore, we conduct a comparative investigation of the distinct AMPK-modulatory profiles of prominent SGLT2 inhibitors and explore the practical applicability of these processes, including possible drawbacks such as the theoretical risk of muscle atrophy associated with persistent AMPK activation. By thoroughly describing the SGLT2-AMPK axis, this review emphasizes its importance as a therapeutic target and offers a framework for understanding the entire range of SGLT2 inhibitor activity in diabetes and associated consequences."

Journal • Review • Cardiovascular • Diabetes • Metabolic Disorders • Muscular Atrophy • Type 2 Diabetes Mellitus • AMPK • FGFR1 • STK11

Urinary dipstick findings and UTI risk with SGLT2 inhibitors: a post hoc analysis of the CANVAS and CREDENCE trials. (PubMed, Nephrol Dial Transplant) - "Although abnormal LE and nitrite were associated with increased UTI risk, canagliflozin did not further increase this risk in these subgroups. These findings do not support routine withholding of SGLT2 inhibitors in patients with dipstick findings suggestive of pyuria or bacteriuria."

Clinical • Journal • Retrospective data • Diabetes • Infectious Disease • Metabolic Disorders • Nephrology • Type 2 Diabetes Mellitus

SGLT-2 INHIBITOR USE IS ASSOCIATED WITH REDUCED RISK OF ATRIAL FIBRILLATION IN HFPEF WITHOUT DIABETES (ACC 2026) - "New SGLT2i users without diabetes (empagliflozin, dapagliflozin, canagliflozin, or ertugliflozin) were compared with matched HFpEF controls without diabetes or SGLT2i exposure. In a large real-world HFpEF cohort without diabetes, SGLT2i initiation was associated with a 16% lower risk of both incident AF and HF hospitalization at 24 months. These findings support an anti-arrhythmic benefit of SGLT2i independent of glycemic effects and highlight the value of early SGLT2i initiation in HFpEF even in the absence of diabetes."

Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders

SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS AND VENOUS THROMBOEMBOLISM EVENTS: A TARGET TRIAL EMULATION (ACC 2026) - " Using the U.S. based-TriNetX dataset, adults with CKD, HF, T2DM or acute myocardial infarction were included into 2 groups: SGLT2i users (canagliflozin, empagliflozin, dapagliflozin) within 1 month of diagnosis and non-SGLT2i users. This suggests that SGLT2i may reduce VTE in addition to having mortality benefit. Further aggregated individual patient data analysis could confirm these findings."

Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Gastroenterology • Heart Failure • Herpes Zoster • Metabolic Disorders • Myocardial Infarction • Nephrology • Peptic Ulcer • Renal Disease • Respiratory Diseases • Type 2 Diabetes Mellitus • Varicella Zoster • Venous Thromboembolism

METABOLIC MODULATION BY SGLT2 INHIBITORS CANAGLIFLOZIN AND DAPAGLIFLOZIN: A NOVEL STRATEGY TO BALANCE ANTITUMOR EFFICACY AND CARDIOTOXICITY IN HER2-POSITIVE BREAST CANCER THERAPY (ACC 2026) - "Background: The clinical use of doxorubicin and trastuzumab in HER2-positive breast cancer is limited by significant cardiotoxicity. These findings suggest that SGLT2 inhibition may represent a novel therapeutic approach in cardio-oncology."

Clinical • Breast Cancer • Congestive Heart Failure • Diabetes • Heart Failure • HER2 Breast Cancer • HER2 Positive Breast Cancer • Metabolic Disorders • Oncology • Solid Tumor • ANXA5 • CASP3 • CASP7 • CXCR4 • HER-2 • IL1B • MYD88 • NLRP3 • SLC2A1 • SLC2A3 • TNFA

CLINICAL OUTCOMES OF SODIUM-GLUCOSE TRANSPORTER 2 (SGLT2) INHIBITORS USE IN PATIENTS WITH PULMONARY HYPERTENSION: INSIGHTS FROM A GLOBAL REAL-WORLD COHORT (ACC 2026) - "Cohort A included PH patients without SGLT2i use (n=141,784), and Cohort B included PH patients prescribed dapagliflozin, empagliflozin, or canagliflozin (n=24,063). In this large global PH cohort, SGLT2 inhibitors were associated with marked reductions in mortality and heart failure hospitalization, with a nonsignificant trend toward fewer lung transplants. These findings suggest SGLT2 inhibitors may represent a novel disease-modifying therapy in PH, warranting randomized trials to confirm their role in improving survival and reducing hospitalizations."

Clinical • Clinical data • Real-world • Real-world evidence • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Euglycaemic ketoacidosis after initiation of tirzepatide in a patient on chronic SGLT2 inhibition and intercurrent colitis (UKKW 2026) - "Case A 44-year-old woman with type 2 diabetes, multiple sclerosis, and coronary artery disease had been on canagliflozin since January 2021...She was discharged on 23 July 2025 on NovoMix 30 insulin (12 units AM, 10 units PM)...Next step Renal services should implement peri-procedure protocols including early suspension of SGLT2i/tirzepatide, ketone-first monitoring, and insulin–dextrose bridging. National audit is needed to quantify incidence, refine drug-hold intervals, and establish euDKA prevention as a measurable NHS safety standard."

Clinical • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Coronary Artery Disease • Diabetes • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Multiple Sclerosis • Nephrology • Septic Shock • Type 2 Diabetes Mellitus

Impact of canagliflozin on the cardiorenal effects of dietary sodium intake in type 2 diabetes: a post hoc analysis of the CREDENCE trial. (PubMed, Diabetologia) - P3 | "In individuals with type 2 diabetes and CKD, LNS intake increases the risk of heart failure and cardiovascular death, while renal outcomes are unaffected by sodium intake. Canagliflozin mitigates the increased cardiovascular risk in individuals with LNS intake, while offering renal protection irrespective of dietary sodium."

Journal • Retrospective data • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Diabetic Nephropathy • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

The SGLT2 Inhibitor Canagliflozin Promotes β-Cell Regeneration and Restores and Stabilises β-Cell Identity in a Polygenic Model of Severe Early-Onset Type 2 Diabetes. (PubMed, J Cell Mol Med) - "Furthermore, cana stabilised β-cell phenotype, restoring the expression of key identity markers while reducing abnormal cell types and the dedifferentiation to precursors and mesenchymal cells. These findings suggest that canagliflozin can promote the regeneration of pancreatic islets and mitigate β-cell dedifferentiation in the early onset of β-cell deficiency."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Pediatrics • Type 2 Diabetes Mellitus

CANAGLIFLOZIN MODULATES PODOCYTE GLUCOSE METABOLISM AND FUNCTION UNDER HYPERGLYCEMIC CONDITIONS (ATTD 2026) - "Taken together, our data suggest that canagliflozin modulates podocyte glucose metabolism by enhancing glycolysis, reducing gluconeogenic flux, and preserving enzymatic activity, and identify a potential mechanism by which SGLT2 inhibitor maintains filtration and barrier integrity under hyperglycemic conditions."

Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Nephrology • Renal Disease • HK1

Acarbose or Canagliflozin vs. Placebo to Ameliorate Post-Bariatric Hypoglycaemia: The Clinical Outcomes of the HypoBar I Randomised Clinical Trial. (PubMed, Diabetes Obes Metab) - P2 | "HypoBar I is the first randomised, placebo-controlled study of the treatment of PBH with acarbose or canagliflozin. Reduction in time below range was not achieved by either treatment; nevertheless, improvements in hypothesis-generating secondary findings merit further investigation and validation. EudraCT number 2022-000157-87."

Clinical • Clinical data • Journal • Hypoglycemia

Effect of anti-tuberculosis drugs on the pharmacokinetics and pharmacodynamics of novel antidiabetic drugs: A scoping review. (PubMed, Pulmonology) - "RIF co-administration with gemigliptin, evogliptin and canagliflozin requires caution and potential requiring dose adjustments, while saxagliptin, dapagliflozin, ertugliflozin and empagliflozin appear safer alternatives. The limited inclusion of DM patients with TB, restricted to one study with latent TB infection, further reduces generalisability. We developed a clinical decision algorithm to support co-treatment in TB - DM cases, but further dedicated studies are warranted to guide optimal co-treatment."

Journal • PK/PD data • Review • Diabetes • Hematological Disorders • Infectious Disease • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Sodium-glucose cotransporter-2 inhibitors to stabilize coronary ather-osclerosis progression after acute myocardial infarction in women and men with diabetes mellitus (clinicaltrialsregister.eu) - P2/3 | N=300 | Not yet recruiting | Sponsor: Humanitas Mirasole S.p.A.

New P2/3 trial • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Diabetes • Metabolic Disorders • Myocardial Infarction

Beneficial Effects of Canagliflozin in Heart Failure Associated With Cardiac and Surgical Procedures. (PubMed, Rev Cardiovasc Med) - "Canagliflozin shows considerable potential as a therapeutic agent for patients with heart failure related to cardiac surgery. However, definitive evidence from large-scale, multicenter randomized controlled trials is warranted to confirm its efficacy and safety, and to optimize perioperative management strategies."

Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

A network meta-analysis of safety and efficacy of sodium-glucose cotransporter 2 inhibitors in heart failure patients. (PubMed, Ann Med Surg (Lond)) - "Sotagliflozin had the greatest reduction in hospitalizations (RR: 0.66, 95% CI 0.57-0.76), followed by empagliflozin (RR 0.73, 95% CI 0.66-0.81). While all SGLT2 inhibitors reduced the likelihood of hospitalizations for HF, canagliflozin did not show a significant benefit in this area. There were no significant differences between the SGLT2 inhibitors in terms of all-cause mortality, MI, stroke, or side effects leading to treatment discontinuation."

Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Myocardial Infarction

Do SGLT2 Inhibitors Influence Parkinson's Disease Risk? A Meta-analysis of Randomized Trials (AAN 2026) - "No eligible data were found for ertugliflozin, enavogliflozin, henagliflozin, ipragliflozin, luseogliflozin, or tofogliflozin...Subgroup analyses showed no significant effect for individual agents: empagliflozin 10 mg (OR 0.64, 95% CI 0.17–2.43), empagliflozin 25 mg (OR 0.33, 95% CI 0.01–8.15), dapagliflozin 10 mg (OR 0.33, 95% CI 0.09–1.23), sotagliflozin (OR 0.25, 95% CI 0.03–2.24), canagliflozin 100 mg (OR 3.00, 95% CI 0.31–28.81), and bexagliflozin (OR 1.50, 95% CI 0.06–36.99)... SGLT2 inhibitors do not significantly alter the risk of PD. These findings support their neurological safety, though longer follow-up and dedicated neurodegenerative outcome trials are warranted."

Retrospective data • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Movement Disorders • Nephrology • Parkinson's Disease • Renal Disease • Type 2 Diabetes Mellitus

IMPACT OF MEDICATION ADHERENCE ON CLINICAL AND ECONOMIC OUTCOMES IN TYPE 2 DIABETES: A SCOPING REVIEW OF REAL-WORLD EVIDENCE (ISPOR 2026) - "Similar results were observed in a study of Medicare Advantage enrollees receiving canagliflozin where adherent patients (PDC >=80%) had significantly greater reductions in HbA1c levels than those who had PDC<80% (1.17% vs. 0.73% reductions, respectively). Numerous studies have demonstrated that adherence to antidiabetic agents in patients with T2DM are associated with beneficial effects for a variety of outcomes, highlighting the importance of interventions to maximize adherence to ensure optimal outcomes in patients with T2DM."

Adherence • Clinical • HEOR • Real-world • Real-world evidence • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus